

Curriculum Vitae

NAME: Howard (Jack) West, MD
DATE, PLACE OF BIRTH: May 2, 1968
Columbus, Ohio
WORK ADDRESS: Swedish Cancer Institute
1221 Madison Street, Suite 200
Seattle, WA 98104
TELEPHONE: Office: 206-386-2424
Fax: 206-386-2746
Direct VM: 425-312-3444
E-MAIL: JackWestMD@gmail.com

TWITTER: @JackWestMD

EDUCATION/TRAINING

9/86 - 6/90 Princeton University; Princeton, NJ
A.B. in Psychology (physiologic)
10/90 - 8/91 University of Cambridge; Cambridge, UK
M. Phil. In Biological Sciences
(thesis defended 1992, degree conferred 1993)
9/91 - 6/96 Harvard Medical School; Boston, MA
M.D., New Pathway Program
6/96 - 10/98 Brigham and Women's Hospital; Boston, MA
Internship/Residency Program in Internal Medicine
Clinical Investigator Track
10/98 – 10/02 Univ. of Washington/Fred Hutchinson Cancer Center; Seattle, WA
Senior Fellowship in Medical Oncology
Supplemental Programs:
3/01 Southwest Oncology Group Young Investigator Program Training
San Antonio, TX and Seattle, WA
7/01 – 8/01 ASCO/AACR Workshop in Clinical Cancer Research
Vail, CO

CURRENT POSITIONS

1/03 – present Medical Oncologist; Medical Director, Thoracic Oncology Program
Swedish Cancer Institute, Seattle, WA
9/07 – present Founder & President, Global Resource for Advancing Cancer Education
(GRACE) (www.cancerGRACE.org), a 501(c)3 nonprofit
10/14 – present Web Editor, JAMA Oncology
2/16 – present Chair, Outreach/Education/Telemedicine Workgroup, Providence Health
System

COMMITTEE PARTICIPATION

2003 – 2008 Patient Care Quality Review Committee, Swedish Medical Center
2003 – present Clinical Research Steering Committee, Swedish Cancer Institute
2004 Co-Chair, Swedish Prostate Cancer Symposium Planning Committee
2004 – 2013 Institutional Review Board, Cancer Research and Biostatistics (CRAB)
2006 Washington State Medical Oncology Society Medical Care Committee
2006 – 2008, 2011-2014 ASCO Scientific Committee, Lung Cancer Track
2013 Chair, ASCO Metastatic Non-small Cell Lung Cancer Track
2013 – present Swedish Medical Center Physician Leadership Forum
2014 Swedish Lung Cancer Symposium Planning Committee
2014 – present Swedish Personalized Medicine Research Program Scientific Committee

OTHER PROFESSIONAL RESPONSIBILITIES

Chief Editor	Medscape Consult
Editorial Board	Journal of Clinical Oncology Clinical Lung Cancer Journal of Medicine Journal of Thoracic Disease www.cancer.net (ASCO website for patient education) Oncology Live
Reviewer	Cancer Cancer Investigation Cancer Letters Clinical Cancer Research Community Oncology Expert Opinion in Biological Therapy Journal of Clinical Oncology Journal of Thoracic Oncology Lancet Lancet Oncology Oncology Nature Clinical Practice Oncology
Chair	Multidisciplinary Interactive Thoracic Oncology Program, Seattle, WA Annual CME Conference (>100 participants/yr), 2005 – 2009 GRACE Patient Forum on Acquired Resistance to Targeted Therapies in Lung Cancer, Boston, MA, 9/14 GRACE Patient Forum on Immunotherapy for Melanoma, Lung, and Renal Cancers, Chicaco, IL, 10/14 Integrating the New Paradigm of Immuno-Oncology into NSCLC Management (CME: >1000 attendees), Denver, CO, 9/15 GRACE Patient Forum on Acquired Resistance to Targeted Therapies in Lung Cancer, San Francisco, CA, 11/15 Personalized Therapies in Lung Cancer, San Francisco, CA, 10/16 Lung Cancer Master Class, Dallas, TX, 2/17
Faculty (Lung Cancer)	UpToDate: Bronchioloalveolar Carcinoma, Non-Surgical Management of Early Stage NSCLC, Systemic Therapy for Early Stage NSCLC, Management of Oligometastatic/Oligoprogressive NSCLC Medscape (regular correspondent, dedicated ASCO correspondent)
<u>HONORS/AWARDS</u>	
1989	Howard Crosby Warren Junior Prize in Psychology
1990	Graduated from Princeton University <i>summa cum laude</i> Fulbright Scholarship to United Kingdom Daniel M. Sachs Memorial Scholarship Overseas Research Scholarship Phi Beta Kappa Society, Princeton University Sigma Xi Society
1992	Howard Crosby Warren Senior Prize in Psychology Albert Schweitzer Society Urban Fellowship Hartford Society Scholarship in Gerontology
1993	Howard Hughes Medical Institute Medical Student Fellowship
1994	Howard Hughes Medical Institute Continued Support Fellowship
1996	Graduated from Harvard Medical School <i>magna cum laude</i>
2001	Southwest Oncology Group Young Investigator
2002	GSK National Medical Oncology Fellows' Forum, Oral Presentation (finalist)
2002 - 2004	Innovators in Lung Cancer, International Program (yearly program x 3 years)

PROFESSIONAL AFFILIATIONS

1999	Washington State Medical Oncology Society American Society of Clinical Oncology
2000	American Association for Cancer Research International Association for the Study of Lung Cancer
2002	Southwest Oncology Group (Lung Cancer & Early Therapeutics) King County Medical Society Washington State Medical Society
2011	American Telemedicine Association
2014	Society for Immunotherapy of Cancer

PUBLICATIONS (PEER-REVIEWED)

- West HL**, Mark GP, & Hoebel, BG. Effects of conditioned taste aversion on extracellular serotonin in the lateral hypothalamus and hippocampus of freely moving rats. *Brain Research*, 1991; 556: 95-100.
- Marston HM, **West HL**, Wilkinson, LJ, Everitt BJ, & Robbins TW. Effects of cytotoxic lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on conditional visual discrimination: Relationship between discrimination performance and choline acetyltransferase activity in the cingulate cortex. *Journal of Neuroscience*, 1994; 14:2009-2019.
- West HL**, Rebeck GW, & Hyman BT. Frequency of the apolipoprotein E e2 allele is diminished in sporadic Alzheimer's disease. *Neuroscience Letters*; 175: 46-48.
- Rebeck GW, Perls TP, **West HL**, Sodhi P, Lipsitz LA, & Hyman BT. Reduced apolipoprotein e4 allele frequency in the oldest old Alzheimer's patients and cognitively normal patients. *Neurology*, 1994; 44: 1513-1516.
- Hyman BT, **West HL**, Rebeck GW, Lai F, & Mann DMA. Neuropathological changes in Down syndrome hippocampal formation: effect of age and apolipoprotein E genotype. *Archives of Neurology*, 1995; 52: 373-378.
- Hyman BT, **West HL**, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, & Stanley HE. Quantitative analysis of senile plaques in Alzheimer's disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21(Down syndrome). *Proceedings of the National Academy of Sciences USA*, 1995; 92: 3586-3590.
- Gomez-Isla T, **West HL**, Rebeck GW, Harr SD, Growden JH, Locasio JT, Perls T, Lipsitz, LA, & Hyman BT. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer's disease. *Annals of Neurology*, 1996; 39: 62-70.
- Gomez-Isla T, Hollister R, **West H**, Mui S, Growdon JH, Petersen RC, Parisi JE, & Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Annals of Neurology*, 1997; 41: 17-24.
- Disis ML, **West HL**, & Schiffman K. Cancer vaccines for the treatment and prevention of non-small cell lung cancer. *Clinical Lung Cancer*, 2000; 1: 294-301.
- Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, & **West HL**. Myalgias & arthralgias associated with paclitaxel: A review of incidence and management. *Oncology*, 2003; 17: 271-277.
- Gandara DR, **West H**, Chansky K, Davies AM, Lau DHM, Crowley J, Gumerlock PH, & Franklin W. Bronchioloalveolar carcinoma: A model for investigating the biology of EGFR Inhibition. *Clinical Cancer Research*, 2004; 10: 4205s-4209s.

PUBLICATIONS (PEER-REVIEWED) (cont.)

West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, & Gandara DR. Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). *Annals of Oncology*, 2005; 16: 1076-1080.

Hirsch FR, Varella-Garcia M, McCoy J, **West H**, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, & Gandara DR. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). *Journal of Clinical Oncology* 2005; 23: 6838-6845, 2005.

West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, & Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. *Journal of Clinical Oncology* 24: 1807-1813, 2006.

Nemunaitis J, Meyers T, Senzer N, Cunningham C, **West H**, Vallieres E, Anthony S, Vukelja S, Berman, B, Tully H, Pappen BV, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, & Cheever MA. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. *Molecular Therapeutics*, 13: 1185-91, 2006.

Hirsch F, Varella-Garcia M, Capuzzo F, McCoy J, Bemis L, Xamier A, Dziadziuszko R, Gumerlock P, Chansky K, **West H**, Gazdar A, Crino L, Gandara D, Franklin W, & Bunn P, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Annals of Oncology*, 18:752-760, 2007.

Garfield DH, Cadranel J, & **West HL**. Bronchioloalveolar carcinoma: The case for two diseases. *Clinical Lung Cancer*, 2008; 9: 24-29.

Chen G, Huynh H, Fehrenbacher L, **West H**, Lara, PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, & Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. *Journal of Clinical Oncology*, 2009; 27: 1401 – 1404.

West HL, Wakelee HA, Perry MC, Belt RJ, Chen R, & Obasaju C. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small cell lung cancer: A phase II clinical trial. *Annals of Oncology* 2009; 20: 850 -856.

West H, Harpole D, & Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. *CHEST*, 2009; 136; 1112-1118.

Green, MR. **West H**, & Socinski, MA. Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer. *J Thor Oncol* 2009; 4: 983-987.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, **West HL**, Azada MC, Morcos PN, Lee R-M, Garcia L, Yu L, Boissarie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, & SH Ou. Safety and efficacy of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol* 2014; 15: 1119-1128.

Camidge DR, Berge EM, Doebele RC, Ballas M, Jahan T, Haigentz M, Hoffman D, Spicer J, **West H**, Lee P, Yang L, Joshi A, Yurasov S, & Mita A. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small cell lung cancer. *J Thorac Oncol* 2014; 9: 1532-1539.

PUBLICATIONS (PEER-REVIEWED) (cont.)

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, **West H**, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Blas B, Puig O, Henschel V, Ou S-HO. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicenter, phase 2 trial. *Lancet Oncol* 2016, 17: 234-2242.

Wilshire CL, Louie BE, Horton MP, Castiglioni M, Aye RW, Farivar AS, **West HL**, Gorden JA, & Vallières E. Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience. *J Thorac Cardiovasc Surg* 2016; 151: 1561-1568.

INVITED CHAPTERS/EDITORIALS

Hoebel BG, Mark GP, & **West HL**. Conditioned neurotransmitter release. Symposium on Regulation of Food Intake, Metabolism, and Energy Balance, 1990; 4: 36.

Hernandez L, Parada M, Baptista T, Schwartz D, **West HL**, Mark GP, & Hoebel BG. Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. *Journal of Clinical Psychiatry*, 1991; 52 Suppl.: 32-40.

Mark GP, Schwartz, DH, Hernandez L, **West HL**, & Hoebel BG. Application of brain microdialysis to the study of motivation and conditioning: Measurements of dopamine and serotonin in freely-behaving rats. In: TE Robinson & JP Justice, Eds.: Microdialysis in Neuroscience. Amsterdam: Elsevier Science Publishing, 1993: pp. 131-136.

West HL, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer's disease and Related Disorders. Chichester, UK: John Wiley & Sons, 1995; pp. 363-370.

Hyman, BT, Sodhi, P, Harr SD, **West HL**, Simonian NA, Rebeck GW, Mui S, & Isla-Gomez T. The paradox of neurofibrillary tangles and senile plaques in Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer's disease and Related Disorders. Chichester, UK: John Wiley & Sons, 1995; pp. 453-460.

Brendel D, **West H**, Hyman S. Hallucinogens. In: D Roberts & L Friedman, Eds., Source Book of Substance Abuse and Addiction. Baltimore, MD: Williams & Wilkins, 1995; pp. 217-230.

Hyman BT, Gomez-Isla T, **West H**, Briggs M, Chung H, Growden JH, & Rebeck GW. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease: Window on molecular epidemiology. *Annals of the New York Academy of Sciences*, 1996; 777: 158-165.

Hyman BT, Hedley-Whyte ET, Rebeck GW, Vonsattel JP, **West HL**, & Growdon JH. Apolipoprotein E ϵ 4/4 in a neuropathologically normal very elderly individual. *Archives of Neurology*, 1996; 53: 215.

Hyman BT, Gomez-Isla T, Rebeck GW, Briggs M, Chung H, **West HL**, Greenberg S, Mui S, Nichols S, Wallace R, & Growdon JH. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. *Annals of the New York Academy of Sciences*, 1996; 802: 1-5.

West H & Kelly K. Pleural malignancies and benign neoplasms of the lung. In ME Hanley & C Welsh, Eds., Current Medical Diagnosis and Treatment in Pulmonary Medicine. New York: Lange Medical Books/McGraw Hill. 2003, pp. 433-439.

INVITED MANUSCRIPTS/CHAPTERS (cont.)

- Gandara DR, **West H**, Albain KS, Werner-Wasik M, Crowley J, & Choy H. Defining the role of radiation therapy in Stage III non-small cell lung cancer: Rationale and design of a new intergroup study. American Society of Clinical Oncology 40th Annual Meeting Educational Book. 2004, pp. 458-462.
- West H**. Incorporation of novel therapies into the management of locally advanced NSCLC. In R Govindan, Ed., Locally Advanced Non-Small-Cell Lung Cancer. New York: CMP Healthcare Media. 2004, pp. 95-105.
- West H** & Garfield D. Bronchioloalveolar Carcinoma: New insights in epidemiology, pathology, and novel strategies. Update chapter for HI Pass, JB Mitchell, DH Johnson, AT Turrisi, & J Minna (Eds.), Lung Cancer: Principles and Practice. Philadelphia: Lippincott, Williams, & Wilkins. Supplement, 2004.
- West H** & Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. *Seminars in Oncology*, 2005; 32: 284-292.
- West H**. EGFR inhibitors fight BAC (Editorial). *Signal*, 2005; 1: 18-20.
- West H**. Emerging approaches to advanced bronchioloalveolar carcinoma. *Current Treatment Options in Oncology*, 2006; 7: 69-76.
- Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, & **West H**. Systemic therapy of bronchioloalveolar carcinoma: results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. *Journal of Thoracic Oncology*, 2006, 1: S32-S36.
- West, H**. Gefitinib in advanced bronchioloalveolar carcinoma (BAC): A case study and review of clinical research on EGFR tyrosine kinase inhibitor therapy for BAC. *American Journal of Hematology/ Oncology*, 2006 5 (suppl 10): 9-12.
- Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, **West H**, & Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. *J Thor Oncol* 2008; 3: 545-555.
- West H** & Garfield DH. Bronchioloalveolar Carcinoma: Not as East as "BAC". *J Thor Oncol*, 2009; 4: 1047-1048.
- West H**, Lilienbaum R, Harpole D, et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. *J Thor Oncol* 2009; 4 (suppl 2): S1029-1039.
- West H**. The role for surgery in stage III non-small-cell lung cancer: Can we reliably select the right patients? *Clin Lung Cancer* 2009; 10: 314-316.
- Stinchcombe TE & **West HL**. Maintenance therapy in non-small-cell lung cancer. *Lancet* 2009; 374: 1398-1400.
- West H**. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value. *J Clin Oncol* 2011; 29: 1095-1098.
- West H**. The evolving role of targeted therapy in early stage and locally advanced non-small cell lung cancer. *Curr Oncol Rep*, 2011, 13: 280-289.
- West H**, & Camidge DR. Have mutation, will travel: Utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. *J Thor Oncol* 2012, 7: 482-484.

INVITED MANUSCRIPTS/CHAPTERS (cont.)

- West H**, deBronkart D, & Demetri GD. A New Model: Physician-Patient Collaboration in Online Communities and the Clinical Practice of Oncology. *ASCO Educational Book* 2012, 443-448.
- West H**. Practicing in partnership with Dr. Google: The growing effect of social media in oncology practice and research. *Oncologist* 2013, 18: 780-782.
- West H**. Patients with advanced non-small-cell lung cancer and marginal performance status: Walking the tight rope toward improved survival. *J Clin Oncol* 2013; 31: 2841-2843.
- West H**, Oxnard GR, & Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer. New strategies and new agents. *ASCO Educational Book* 2013: 272-278.
- West H**. Afatinib for advanced mutation NSCLC: New hope or new Coke? *J Commun Supp Oncol* 2014; 12: 115-117.
- West H**. Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. *Clin Adv Hem Onc* 2014; 12: 593-600.
- West H**. Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC), In Lung Cancer, 4th Ed (Roth JA, Cox JD, Hong WK, Chang JY, Blackmon S, & Tsao A, eds.), 2013. Wiley, Oxford.
- Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, **West H**, Whitlock S, & Somerfield MR. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the American Pathologists/International Society for the Study of Lung Cancer/Association of Molecular Pathologists guideline. *J Clin Oncol*, 2014; 32: 3673-3679.
- West H**. The failure of figitumumab: the danger of taking shortcuts in drug development. *Ann Oncol* 2015: 26: 447-448.
- West H**. Individualizing adjuvant therapy for early stage non-small cell lung cancer: we see the destination, but we don't yet know the route. *J Thorac Dis* 2015; 7: 235-237.
- West H**. Immune checkpoint inhibitors. *JAMA Oncol*, 2015; 1: 115.
- West H**. Malignant pleural effusions. *JAMA Oncol*, 2015; 1: 260.
- West H**. Circulating tumor cells. *JAMA Oncol* 2015, 1: 394.
- West H** & Jin J. Neoadjuvant therapy. *JAMA Oncol* 2015, 1: 550.
- West H** & Jin J. Adjuvant therapy. *JAMA Oncol* 2015, 1: 698.
- West H** & Jin J. The evolution of a cancer. *JAMA Onc* 2015, 1: 850.
- West H** & Jin J. Performance status in cancer patients. *JAMA Onc* 2015, 998.
- West H** & Jin J. Transarterial chemoembolization. *JAMA Oncol* 2015, 1: 1178.
- West H**. The slippery slope of broadening eligibility and weak endpoints: defending the *oligo* in oligometastatic non-small cell lung cancer. *JAMA Oncol* 2015, 1: 1219-1220.
- West H**. Balancing benefit, risk, and time to new cancer therapies. *JAMA Oncol* 2016, 2: 122.

INVITED MANUSCRIPTS/CHAPTERS (cont.)

West H & Jin J. Portacaths. *JAMA Oncol* 2015, 2: 152.

Bates G, Taub R, & **West H**. Fertility and cancer treatment. *JAMA Oncol* 2016, 2: 284.

West H. Young patients with lung cancer – an understudied population. *JAMA Oncol* 2016, 2: 321.

Subbiah V & **West HL**. Bone complications in patients with cancer. *JAMA Oncol* 2016, 695.

West H. No solid evidence, only a hollow argument for universal tumor sequencing; Show me the data. *JAMA Oncol* 2016, 2: 717-718.

West H & Jin J. Lymph nodes and lymphadenopathy. *JAMA Oncol* 2016, 2: 971.

Subbiah V & **West HL**. Jaundice (hyperbilirubinemia) in cancer. *JAMA Oncol* 2016, 2: 1236.

West H. Can we define and reach precise goals for precision medicine in cancer care? *J Clin Oncol* 2016, 34: 3595-3597.

Gupta A & **West H**. Mucositis (or stomatitis). *JAMA Oncol* 2016, 2: 1379.

West H. Highlights of recent studies of metastatic non-small cell lung cancer. *JAMA Oncol* 2016, doi: 10.1001/jamaoncol.2016.3676

West H. Bringing adjuvant chemotherapy for resected non-small cell lung cancer into real-world practice: Better late than never? *JAMA Oncol* 2017; doi: 10.1001/jamaoncol.2016.5798

West H. Commentary: Scalp Cooling Alopecia Prevention Trial (SCALP). *JAMA Oncol* 2017, in press.

ABSTRACTS

West HL, Schwartz DH, & Hoebel BG. Local injection of serotonin into the lateral hypothalamus suppresses food intake. *Society for Neuroscience Abstracts*, 1989; 15:1281.

West HL, Robbins TW, & Everitt BE. AMPA-induced cholinergic lesions of the vertical limb of the diagonal band (VDB) impair performance of a conditioned visual discrimination (CVD) task. *Society for Neuroscience Abstracts*, 1991; 17: 138.

Hoebel BG, Mark GP, & **West HL**. Conditioned neurotransmitter release as measured by microdialysis. *Clinical Neuropharmacology*, 1992; 15 Suppl. 1A: 704A

West HL, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer's disease. *Neurobiology of Aging*, 1994; 15: S28.

Hyman BT, **West HL**, Harr S, Gomez-Isla T, & Mui S. Quantitative neuropathology in Alzheimer's disease: neuronal loss in high order association cortex parallels dementia. *Neurobiology of Aging*, 1994; 44: S141.

West HL, Rebeck GW, Perls T, Sodhi P, Lipsitz L, & Hyman BT. The prevalence of apolipoprotein E4 in the oldest old: connections with Alzheimer's disease. *Neurology*, 1994; 44: A325.

West HL, Taylor LP, & Jacobs AD. Association of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) with progressive sensory polyneuropathy/ataxia: A case report. *Blood*, 1999; 94 Suppl 1: 293b.

ABSTRACTS (cont.)

West HL, Livingston, RB, Wood DE, Vallieres E, Yaziji H, & Gown A. HER-2/neu (HER2), as assessed by immunohistochemistry (IHC), is rarely expressed in stage I resected non-small cell lung cancer (NSCLC) and does not predict clinical outcome. *J Clin Oncol* 2001; 20: 333a (#1327).

Vallieres E, **West HL**, Hunt K, Einck J, & Stelzer K. Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant radiation therapy for malignant pleural mesothelioma: a case series. *J Clin Oncol* 2001; 20: 279b (#2867).

West H, Livingston R, Wood D, Vallieres E, Giarritta S, Yaziji H, & Gown AM. Overexpression of cyclooxygenase-2 (COX-2) is associated with more aggressive clinical behavior of non-small cell lung cancer. *Lung Cancer* 34 (Suppl 1); 45-46.

West H, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. *J Clin Oncol* 2002; 21: 309a (#1235).

Miller DL, Vallieres EC, **West H**, Okuno SH, Marks RS. Operative morbidity and mortality after induction chemotherapy and extrapleural pneumonectomy for malignant pleural mesothelioma. *Proceedings of the European Association for Cardiothoracic Surgery* 2002; 16.

Franklin WA, Gumerlock PH, Crowley J, Chansky K, **West H**, & Gandara DR. EGFR, HER2, and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): Analysis of SWOG 9714 and lung SPORE tissue samples. *J Clin Oncol* 2003; 22: 620 (#2493).

Lau DHM, **West H**, Laptalo L, Geraghty E, Seibert A, Crowley J, & Gandara D. Computer-assisted image analysis of response in bronchioloalveolar carcinoma to ZD1839. *Lung Cancer* 2003; 41: S55.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, & Gandara DR. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG S0126. *Lung Cancer* 2003; 41: S56.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) Therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. *J Clin Oncol* 2004; 23: 618 (#7014).

Franklin WA, Chansky K, Gumerlock PH, Crowley J, Hirsch FR, **West H**, Crowley JJ, & Gandara DR. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). *J Clin Oncol* 2004; 23: 619 (#7015).

Gold PJ, Refice S, & **West H**. Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors. *J Clin Oncol* 2005; 23: 619 (#2120).

Johnson BE, Ma P, **West H**, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, & Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. *J Clin Oncol* 2005; 23: 645 (#7102).

Gumerlock PH, Holland WS, Chen H, Franklin WA, Hirsch FR, Mack PC, Davies AM, **West H**, & Gandara DR. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group trial S0126 of bronchioloalveolar carcinoma (BAC) patients treated with gefitinib. *J Clin Oncol* 2005; 23: 623 (#7008).

ABSTRACTS (cont.)

- Hirsch FR, Gandara DR, McCoy J, Crowley J, **West H**, Gumerlock PH, Bunn PA, Franklin WA, & Varella-Garcia M. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). *J Clin Oncol* 2005; 23: 628 (#7030).
- West H**, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. *Proceedings of the American Society of Clinical Oncology* 2005; 23: 645 (#7117).
- Hyunh MT, Lehrenbacher L, **West H**, Davies A, Simmons J, Lara P, Yarorkovsky L, Russin M, Gandara DR, & Lau D. A multi-institution phase II trial of irinotecan and carboplatin for extensive or relapsed small cell lung cancer. *J Clin Oncol* 2005; 23: 662 (#7169).
- Heymach J, **West H**, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, & Johnson B. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study. *Lung Cancer* 2005; 49 (Suppl 2): S-247-248 (A#P-497).
- Hirsch FR, Franklin WA, McCoy J, Capuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, **West H**, Gandara DR, & Bunn P.A, Jr. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. *J Clin Oncol* 2006; 24: 382 (A#7072).
- West H**, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. *J Clin Oncol* 2006; 24: 393 (A#7116).
- West H**, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. *J Clin Oncol* 2007; 25: 430s (A#7685).
- West H**, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. *J Thor Oncol* 2007; 2(8) Suppl 4:S334 (A#B1-04)
- Green MR, **West H**, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, & Iovino L. Management of N3 stage IIIB NSCLC: Changes in US physician behavior following ASCO 2007. *J Clin Oncol* 2008; 26: A#7579.
- West H**, Chansky K, Franklin WA, Hirsch FR, Crowley JJ, Lau DH, & Gandara DR. Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. *J Clin Oncol* 2008; 26: A#8047.
- Hanna NH, Estes D, Arnott J, Marcotte A, Hannah A, Sidor CF, **West H**, Clamon G, & Hoang T. Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2009; A#e19005.
- Wakelee H, Gettinger S, Engelman J, Jänne P, **West H**, Subramaniam D, Leach J, Wax M, Yaron Y, & Lara P. A phase 1b/2 study of XL184 (BMS 907351) with & without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010; 28 15s (suppl., A#3017).
- Green MR, Wozniak AJ, Willey J, Lemke KE, & **West HJ**. Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010; 28 15s (suppl., A#7568).

ABSTRACTS (cont.)

West H, Moon J, Hirsch F, Mack PC, Wozniak A, Redman M, & Gandara DR. The combination of erlotinib/bevacizumab in never-smokers with advanced lung adenocarcinoma: Southwest Oncology Group (SWOG) trial 0636. *J Thor Oncol* 2011; 6(6) Suppl 2:S552-553 (A#MO-09-03-4).

West H, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D, Fehrenbacher L, Bury MJ, Redman MW, & Gandara DR. SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). *J Clin Oncol* 2012; 30 (suppl., A#7517).

Mack PC, Moon J, **West H**, Franklin WA, Varella-Garcia M, Wynes MW, Wozniak AJ, Redman MW, Hirsch FR, Gandara DR. Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC. *J Clin Oncol* 2012; 30 (suppl., A#7552).

Gandhi L, Shaw A, Gadgeel SM, Riely G, Cetnar J, **West H**, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter AH, Bordogna W, Balas B, Puig O, Henschel, Ou S-HI. A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an *ALK+* non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). *J Clin Oncol* 33, 2015 (suppl; abstr 8019).

Spigel DR, Reckamp KL, Rizvi NA, Poddubskaaya E, **West H**, Eberhardt WEE, Baas P, Antonia SJ, Pluzanski A, Vokes EE, Holgado E, Waterhouse DM, Ready N, Gainor JF, Aren OR, Horn L, Paz-Ares L, Baudalet C, Lestini BJ, Brahmer JR. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *J Clin Oncol* 33, 2015 (suppl; abstr 8009).

Yu HA, Oxnard GR, Spira AI, Horn L, Weiss J, Feng Y, **West H**, Giaccone G, Evans TL, Kelly RJ, Fleege T, Poondru S, Jie F, Aoyama K, Foley MA, Whitcomb D, Keating AT, Krivoshik AP. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation-positive NSCLC. *J Clin Oncol* 33, 2015 (suppl; abstr 8083).

Liu SV, Arrawal C, Carter C, Gerber DE, Gitlitz B, Horn L, Solomon B, Stinchcombe T, Villaruz L, **West H**, Kroll S, Pearce T, & Camidge Dr. A phase 2 study of tarloxotinib bromide (TH-4000) in patients with EGFR mutant, T790M-negative, advanced NSCLC progressing on an EGFR TKI. *J Thor Oncol* 2015.

Langer CJ, Hirsh V, Amiri K, Ko A, Knoble JL, Johnson ML, Jotte RM, McLeod M, Ong TJ, Page RD, Spigel DR, **West H**. Quality of life (QoL) by response: An interim analysis of patients (pts) with squamous (SCC) NSCLC treated with *nab*-paclitaxel/carboplatin (*nab*-P/C) induction therapy in the phase III ABOUND.sqm study. *J Clin Oncol* 34, 2015 (suppl 7S, abstr 63).

Kim D-W, Tiseo M, Ahn M-J, Reckamp RL, Hansen KH, Kim S-W, Huber RM, **West H**, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares LG, Smit EF, Kim ES, Reichmann WG, Kerstein D, Haluska FG, Camidge DR. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory *ALK+* non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). *J Clin Oncol* 34, 2016 (suppl; abstr 9007).

Liu SV, Aggarwal C, Brzezniak C, Doebele RC, Gerber DE, Gitlitz B, Horn L, Solomon BJ, Stinchcombe T, Villaruz LC, **West H**, Kroll S, Pearce TE, Camidge DR. Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-mutant, T790M-negative NSCLC progression on an EGFR TKI. *J Clin Oncol* 34, 2016 (suppl; abstr TPS9100).

ABSTRACTS (cont.)

Yu HA, Spira AI, Horn L, Weiss J, **West H**, Giaccone G, Evans TL, Kelly RJ, Desai BB, Krivoschik A, Fleege TE, Poondru, Jie F, Aoyama K, Whitcomb DA, Keating AT, Oxnard GR. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer. Interim results from an ongoing phase 1 study. *J Clin Oncol* 34, 2016 (suppl; abstr 9050).

KEY PRESENTATIONS

West HL, Schwartz DH, & Hoebel BG. Local injection of serotonin into the lateral hypothalamus suppresses food intake. Poster presented at Society for Neuroscience Conference: Phoenix, AZ, 10/89.

West HL, Mark GP, & Hoebel. Effects of conditioned taste aversion acquisition and expression on serotonin release in the lateral hypothalamus and hippocampus as measured by microdialysis. Poster presented at New Jersey Neuropsychopharmacology Society Conference: Princeton, NJ, 5/90.

West HL, Mark GP, & Hoebel BG. Effects of conditioned taste aversion (CTA) on serotonin release in the lateral hypothalamus and hippocampus. Poster presented at Society for Neuroscience Conference: St. Louis, MO, 11/90.

West HL, Robbins TW, & Everitt, BE. AMPA-induced cholinergic lesions of the vertical limb of the diagonal band (VDB) impair performance of a conditional visual discrimination (CVD) task. Poster presented at Society for Neuroscience Conference: New Orleans, LA, 11/91.

West HL, Rebeck GW, Perls TP, Lipsitz LA, Sodhi, P, & Hyman BT. Apolipoprotein E4 prevalence in the oldest old: Connections with Alzheimer's disease. Talk delivered at American Academy of Neurologists Annual Conference: Washington, DC, 5/94.

West HL. The apolipoprotein E e4 allele is a risk factor for development of Alzheimer's disease but does not influence its clinical progression. Talk delivered at Howard Hughes Medical Institute Research Fellowship Conference: Washington, DC, 5/94.

West HL, Livingston, RB, Wood DE, Vallieres E, Yaziji H, & Gown A. HER-2/neu (HER2), as assessed by immunohistochemistry (IHC), is rarely expressed in stage I resected non-small cell lung cancer (NSCLC) and does not predict clinical outcome. Poster presented at the American Society for Clinical Oncology Annual Conference: San Francisco, CA, 5/01.

West H, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. Poster presented at the American Society for Clinical Oncology Annual Conference: Orlando, FL, 5/02.

West H, Franklin WA, Gumerlock PH, Lau DHM, Crowley J, Chansky K, Vance R, & Gandara DR. Gefitinib in bronchioloalveolar carcinoma (BAC): SWOG 0126 experience. Talk delivered at Fourth International Lung Cancer Congress: Maui, HI, 6/03.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, & Gandara DR. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG S0126. Talk delivered at 10th World Conference on Lung Cancer: Vancouver, BC, Canada, 8/03.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) Therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Talk delivered at Innovators in Lung Cancer conference: Boston, MA, 5/04.

KEY PRESENTATIONS (cont.)

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Talk delivered at the American Society for Clinical Oncology Annual Conference: New Orleans, LA, 6/04.

West H, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Poster presented at the American Society for Clinical Oncology Annual Conference: Orlando, FL, 5/05.

West H, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. Poster presented at the American Society for Clinical Oncology Annual Conference: Atlanta, GA, 6/06.

West H, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Poster presented at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/07.

West H, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Talk delivered at 12th World Conference on Lung Cancer: Seoul, Korea. 9/07.

West H, Chansky K, Franklin WA, Hirsch FR, Crowley JJ, Lau DH, & Gandara DR. Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. Poster presented at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/08.

West H. Highlights in Small Cell Lung Cancer and Stage I-III Non-Small Cell Lung Cancer. Commentary presented at Best of ASCO Conference: Seattle, WA, 7/10.

West H. Learning as if your life depends on it. Patient self-education to improve cancer care. Talk delivered at TEDxOverlake: Redmond, WA, 6/11.

West H, Moon J, Hirsch F, Mack PC, Wozniak A, Redman M, & Gandara DR. The combination of erlotinib/bevacizumab in never-smokers with advanced lung adenocarcinoma: Southwest Oncology Group (SWOG) trial 0636. Talk delivered at 13th World Conference on Lung Cancer: Amsterdam, Netherlands, 7/11.

West H. Highlights in small cell lung cancer and stage I-III non-small cell lung cancer. Best of ASCO, Seattle, WA, August, 2011.

West H, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D, Fehrenbacher L, Bury MJ, Redman MW, & Gandara DR. SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). Poster presented at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/12.

West H. Physician participation online: Adapting to a new model of interaction between doctors and engaged patients. Talk at educational session delivered at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/12.

KEY PRESENTATIONS (cont.)

KEY PRESENTATIONS (cont.)

West H. Changes afoot: A new model of interaction between doctors and engaged patients. Talk delivered at LIVESTRONG REV Forum, Austin, TX, 10/12.

West H. The clinical perspective on acquired resistance: Identifying and overcoming barriers. Talk at educational session delivered at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/13.

West H. Right patient, right drug, right time. Commentary presented at Metastatic Non-Small Cell Lung Cancer Oral Abstracts Session, American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/14.

West H. Highlights in Metastatic Non-Small Cell Lung Cancer from ASCO 2014. Best of ASCO Conference, Seattle, WA, 8/14.

West H. Social Media as a Tool for Physician and Patient Education. Pre-conference symposium, American Society for Clinical Oncology Annual Conference: Chicago, IL, 5/15.

West H. Meet the experts: squamous cell lung cancer. Talk delivered at 16th World Conference on Lung Cancer: Denver, CO. 9/15.

West H. New kinase targets (expert commentary). Talk delivered at 16th World Conference on Lung Cancer: Denver, CO. 9/15.

West H. Highlights of the Day: Metastatic Non-Small Cell Lung Cancer. American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/16.